Viking Therapeutics, Inc.
corporate_fare Company Profile
Viking Therapeutics, Inc. (NASDAQ:VKTX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 28 items for VKTX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-29, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 8/10, with 10 rated 8 or above. Recent SEC coverage for VKTX spans 8-K, 424B5, FWP, S-3ASR.
Recent high-impact activity:
- Q3 Loss Nearly Doubles and Misses Estimates, but Weight-Maintenance Data Lifts Shares 6%
- Viking Q3 Loss of $1.55/Share Blows Past $1.07 Consensus as Obesity Spend Ramps
- Viking Q3 Loss Widens to $183.2M as R&D Hits $166.8M; Cash $960M
- Viking Q3 Loss Widens to $183M as Obesity Phase 3 Spend Ramps; $960M Cash
- Viking Closes $548M Concurrent Offering After Full Over-Allotment Exercise
Financial Snapshot
Short Interest & Short Volume
5.37 days to coverFINRA reported short interest of 24,163,022 shares in VKTX as of the October 30, 2026 settlement, a 5.4% decrease from the prior period — about 5.4 days to cover at its recent average daily volume. On November 19, 2026, 51.4% of VKTX volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Moderate riskFiling-implied dilution signals for VKTX, detected from its recent SEC filings · based on capital-structure filings through 2026-09-25.
Upsized $500M Concurrent Offering Finalized · Convertible Note Terms Set
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →